10-Q: Akero Therapeutics Q3 2025: Novo Nordisk Merger Advances

Akero Therapeutics reports Q3 2025 results, highlighting progress in its Phase 3 SYNCHRONY program for MASH and the pending acquisition by Novo Nordisk for $54.00 cash plus a $6.00 CVR per share.

Summary

• A Merger Agreement with Novo Nordisk A/S was announced on October 9, 2025, for $54.00 cash per share plus one contingent value right (CVR) representing $6.00 in cash if a specified milestone is achieved.
• The company is expected to become a wholly-owned subsidiary of Novo Nordisk, with the merger closing anticipated around year-end 2025.
• The lead product candidate, efruxifermin (EFX), is in an ongoing global Phase 3 SYNCHRONY program for metabolic dysfunction-associated steatohepatitis (MASH), comprising three clinical trials (Outcomes, Histology, and Real-World) with an expected total enrollment of about 3,500 patients.
• Preliminary topline week 96 results from the Phase 2b SYMMETRY trial (compensated cirrhosis F4 MASH) showed 39% of patients treated with 50mg EFX experienced cirrhosis reversal with no worsening of MASH, compared to 15% for placebo (p=0.009).
• Preliminary topline week 96 results from the Phase 2b HARMONY trial (pre-cirrhotic MASH F2-F3) showed a 75% response rate for 50mg EFX and 46% for 28mg EFX, compared to 24% for placebo, for a 1-stage improvement in fibrosis with no worsening of MASH.
• Enrollment for the double-blind portion of the SYNCHRONY Real-World trial was completed in January 2025, with results expected in the first half of 2026.
• Net loss for the three months ended September 30, 2025, was $81.6 million, an increase from $72.7 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $222.8 million, an increase from $182.0 million for the same period in 2024.
• Research and development expenses increased by $6.7 million (9%) for the three months and $39.5 million (22%) for the nine months ended September 30, 2025, primarily driven by the Phase 3 SYNCHRONY program.
• General and administrative expenses increased by $1.9 million (20%) for the three months and $5.1 million (17%) for the nine months ended September 30, 2025.
• Cash, cash equivalents, and marketable securities totaled $988.3 million as of September 30, 2025.
• The company repaid its $35.0 million Term Loan with Hercules on September 23, 2025, resulting in a $1.6 million loss on extinguishment.
• A class-action lawsuit, Klobus v. Akero Therapeutics, Inc., related to alleged misstatements regarding the Phase 2b SYMMETRY study, was dismissed with prejudice on August 15, 2025, but Lead Plaintiffs filed a Notice of Appeal on September 12, 2025.

Sentiment

Score: 8

Explanation: The pending acquisition by Novo Nordisk at a substantial premium, coupled with positive Phase 2b clinical trial data for EFX, significantly de-risks the company for shareholders, despite ongoing operational losses and R&D expenses. The merger provides a clear, favorable outcome for investors.

Positives

• The proposed acquisition by Novo Nordisk at a significant premium ($54.00 cash plus a $6.00 CVR per share) provides a clear and favorable exit strategy for shareholders.
• EFX Phase 2b SYMMETRY trial demonstrated statistically significant cirrhosis reversal (39% for 50mg EFX vs. 15% placebo) in patients with compensated cirrhosis (F4) MASH.
• EFX Phase 2b HARMONY trial showed robust fibrosis improvement (75% for 50mg EFX vs. 24% placebo) in pre-cirrhotic MASH (F2-F3) patients at week 96.
• Enrollment for the double-blind portion of the SYNCHRONY Real-World trial has been completed, indicating progress in the Phase 3 program.
• The company maintains a strong cash, cash equivalents, and marketable securities position of $988.3 million as of September 30, 2025, which is expected to fund operations for at least 12 months if the merger is not consummated.
• The $35.0 million Term Loan with Hercules was fully repaid on September 23, 2025, reducing debt obligations.
• The Klobus v. Akero Therapeutics, Inc. class-action lawsuit was dismissed with prejudice on August 15, 2025, although an appeal has been filed.

Negatives

• Net loss increased to $81.6 million for the three months and $222.8 million for the nine months ended September 30, 2025, compared to the prior year periods.
• The accumulated deficit reached $1,049.0 million as of September 30, 2025, reflecting significant historical losses.
• The company expects to continue incurring significant operating losses for the foreseeable future, particularly if the merger with Novo Nordisk is not completed.
• A $1.6 million loss on extinguishment of the loan payable was recorded in connection with the Hercules Term Loan repayment.
• The company is heavily dependent on the success of EFX, its only product candidate, which carries inherent development and commercialization risks.
• The pending merger with Novo Nordisk imposes restrictions on business activities and diverts management's attention from day-to-day operations.
• A termination fee of $165.0 million would be payable to Novo Nordisk under certain specified circumstances if the merger agreement is terminated.
• Despite dismissals, the ongoing appeal in the Klobus v. Akero Therapeutics, Inc. lawsuit presents continued legal risk and potential defense costs.

Risks

• The pending transaction with Novo Nordisk A/S may not be completed within the anticipated timeframe or at all, which could adversely affect business, financial results, and/or operations.
• Restrictions on business activities while the Merger Agreement is in effect may prevent the company from pursuing strategic business opportunities.
• The pendency of the transaction could adversely affect business relationships with employees and third parties and divert management attention.
• The company may be required to pay a $165.0 million termination fee to Novo Nordisk if the Merger Agreement is terminated under certain circumstances.
• Significant direct and indirect costs will continue to be incurred as a result of the pending transaction.
• Enrollment and retention of patients in clinical trials is an expensive and time-consuming process, made more difficult by MASH diagnosis challenges, competition, and public health crises.
• Substantial competition exists in the biotechnology industry, potentially leading to others developing or commercializing products more successfully.
• Failures or delays in clinical trials, or ambiguous/negative results, could increase costs and delay revenue generation.
• Clinical development is uncertain, and EFX trials may experience delays, adversely affecting regulatory approvals or commercialization.
• Reliance on third parties to conduct clinical trials poses risks if they do not successfully carry out contractual duties or meet deadlines.
• The manufacture of product candidates is complex, and difficulties in production or failure to meet regulatory standards could delay supply or impact cost structure.
• The company is heavily dependent on the success of EFX, its only product candidate.
• Failure to develop and successfully commercialize other product candidates would harm business and future prospects.
• Developing EFX in combination with other therapies exposes the company to additional risks.
• Inability to discover, develop, receive regulatory approval for, and commercialize EFX and future product candidates would impair business expansion and strategic objectives.
• Significant payments may be required under the license agreement for EFX with Amgen.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable.
• Harmful side effects of products after approval could lead to revocation of approvals and costly product liability claims.
• Relationships with customers and third-party payors are subject to anti-kickback, fraud and abuse, transparency, and other healthcare laws, with potential for criminal sanctions and civil penalties.
• The company has incurred significant losses since inception and expects to incur losses for the foreseeable future.
• The company has a limited operating history, has not generated any revenue to date, and may never become profitable.
• If the merger is not consummated, additional capital will be required to finance operations, which may not be available on acceptable terms, or at all.
• Inability to protect confidential information and trade secrets would harm business and competitive position.
• Involvement in lawsuits to protect or enforce intellectual property could be expensive, time-consuming, and unsuccessful.
• Third parties may initiate legal proceedings alleging infringement of their intellectual property rights.
• Claims by third parties asserting misappropriation of intellectual property or ownership of the company's intellectual property.
• Intellectual property rights may not address all potential threats or provide adequate protection.
• Issued patents covering product candidates could be found invalid or unenforceable if challenged in court or the USPTO.
• Changes in patent law could diminish the value of patents in general.
• Limited experience in conducting clinical trials and never having obtained approval for any product candidates.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• The advancement of healthcare reform may negatively impact the ability to profitably sell product candidates, if approved.
• Relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations.
• Failure to comply with health, data protection, and national security laws and regulations could lead to government enforcement actions, private litigation, and/or adverse publicity.
• Governments outside the United States tend to impose strict price controls, which may adversely affect revenue.
• Healthcare insurance coverage and reimbursement may be limited or unavailable for product candidates, if approved.
• Activities in the United States subject the company to various laws relating to foreign investment and the export of certain technologies.
• Subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations.
• Inadequate funding for the FDA, SEC, and other government agencies, including from government shutdowns, could hinder their ability to perform normal business functions.
• Difficulties in managing growth could adversely affect operations.
• Unfavorable global economic conditions, including geopolitical tensions (e.g., Middle East conflict impacting clinical trial sites in India, Israel, Turkey), inflation, and interest rates, could adversely affect business.
• Adverse developments affecting the financial services industry could adversely affect current and projected business operations.
• Significant costs and time/effort are incurred as a result of operating as a large accelerated public company.
• Failure to maintain an effective system of internal controls over financial reporting could lead to inaccurate financial reporting or fraud.
• Compromise of information technology systems or data could result in adverse consequences.
• Use and generation of hazardous materials may expose the company to material liability.
• The market price of the stock may be volatile, and the company could incur significant costs from class action securities litigation.
• The company does not intend to pay dividends on common stock, so returns will be limited to stock value appreciation.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about the business, stock price and trading volume could decline.
• Anti-takeover provisions under organizational documents and Delaware law could delay or prevent a change of control.
• Bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain actions and federal district courts for Securities Act claims, potentially limiting stockholders' ability to obtain a favorable judicial forum.
• Changes in tax laws could adversely affect business and financial condition.
• The company might not be able to utilize a significant portion of net operating loss carryforwards and research and development tax credit carryforwards due to ownership changes.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future, particularly if the merger with Novo Nordisk is not completed. If the merger is not consummated, additional funding will be required to complete EFX clinical development, commercialize EFX (if approved), and pursue in-licenses or acquisitions of other product candidates. Results from the SYNCHRONY Real-World trial are expected in the first half of 2026. The merger with Novo Nordisk is expected to close around year-end 2025, after which the company's common stock will no longer be publicly listed.

Management Comments

• "We expect that our research and development expenses will increase substantially in the near term and in the future, due to planned manufacturing and clinical development activities necessary to support the ongoing development of EFX."
• "We expect to continue to incur significant expenses for at least the next several years as we advance EFX through later-stage clinical development, develop additional product candidates and seek regulatory approval of any product candidates that complete clinical development."
• "If the merger with Novo is not completed, we expect that we will require additional funding to complete the clinical development of EFX, commercialize EFX, if it receives regulatory approval, and pursue in-licenses or acquisitions of other product candidates."
• "We expect that its existing cash, cash equivalents, short-term and long-term marketable securities of $988,316 as of September 30, 2025, will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of these condensed consolidated financial statements."

Industry Context

The company operates in the highly competitive biotechnology industry, specifically targeting metabolic dysfunction-associated steatohepatitis (MASH). EFX, an FGF21 analog, is being developed amidst significant competition from multinational pharmaceutical and specialized biotechnology companies also pursuing MASH treatments, including those developing GLP-1 therapeutics. The filing notes the March 2024 marketing approval of Rezdiffra™ and potential approvals for other investigational MASH drugs, indicating a rapidly evolving competitive landscape. The company believes EFX may be used in combination with other therapies, particularly GLP-1s, for patients with both MASH and type 2 diabetes.

Comparison to Industry Standards

• Many competitors, including AstraZeneca PLC/MedImmune LLC, Boehringer Ingelheim AG, Eli Lilly and Company, GSK plc, Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc., and Roche Holding AG, possess substantially greater financial, technical, human, and other resources.
• Competitors often have significantly more experience in undertaking nonclinical studies, human clinical trials, and obtaining regulatory approvals for pharmaceutical products.
• The March 2024 marketing approval of Rezdiffra™ (Madrigal Pharmaceuticals, Inc.) for MASH is a direct competitive factor that may adversely affect patient enrollment in the company's Phase 3 trials.

Management Changes

Corporate Governance

Legal Proceedings

• A class-action lawsuit, Klobus v. Akero Therapeutics, Inc., was filed on April 26, 2024, alleging misstatements and omissions regarding the Phase 2b SYMMETRY study.
• The U.S. District Court for the Northern District of California dismissed the suit in its entirety without prejudice on May 5, 2025, and again with prejudice on August 15, 2025.
• Lead Plaintiffs filed a Notice of Appeal on September 12, 2025, with their opening brief due on December 5, 2025.
• The company intends to vigorously defend against the lawsuit, but the probability or amount of potential related costs is not yet determinable due to the early stage of the appeal.

Stakeholder Impact

• Shareholders: Significant positive impact due to the proposed acquisition by Novo Nordisk at a premium, offering $54.00 cash plus a $6.00 CVR per share. Potential negative impact if the merger fails or if the CVR milestone is not met.
• Employees: Uncertainty about roles following the merger, potential challenges in retention. Management attention is diverted to merger completion.
• Customers/Patients: Potential for EFX to become an important medicine for MASH if approved, with its development continuing under Novo Nordisk's resources.
• Creditors: Positive impact from the repayment of the Hercules Term Loan.
• Collaborators/Vendors: Uncertainty regarding future business relationships due to the pending transaction, as counterparties may defer decisions or seek to change existing relationships.

Next Steps

• Closing of the merger with Novo Nordisk A/S is expected around year-end 2025.
• Reporting primary endpoint results of the Phase 3 SYNCHRONY program (Outcomes, Histology, and Real-World).
• Results from the SYNCHRONY Real-World trial are expected in the first half of 2026.
• Lead Plaintiffs' opening brief in the Klobus v. Akero Therapeutics, Inc. appeal is due on December 5, 2025.
• Negotiating terms for commercial supply with Boehringer Ingelheim and Vetter for EFX.
• Continued evaluation of the impact of the One Big Beautiful Bill Act (OBBBA) on financial statements.
• Evaluating the provisions of ASU No. 2024-03 and ASU No. 2025-01 for future condensed consolidated financial statements.

Key Dates

Recommendation

The pending acquisition by Novo Nordisk at a significant premium ($54.00 cash + $6.00 CVR) provides a strong, near-term positive catalyst for shareholders. The offer price is substantially above the current trading range, making it an attractive arbitrage opportunity. The positive Phase 2b clinical data for EFX further validates the asset's potential, which is now being acquired by a major pharmaceutical player, de-risking the investment significantly. While there are termination risks, the overall probability of deal completion appears high, and the CVR offers additional upside.

Keywords

Akero Therapeutics, EFX, efruxifermin, MASH, NASH, metabolic dysfunction-associated steatohepatitis, MASLD, NAFLD, liver disease, fibrosis, cirrhosis, FGF21, clinical trials, Phase 3 SYNCHRONY, SYNCHRONY Outcomes, SYNCHRONY Histology, SYNCHRONY Real-World, SYMMETRY, HARMONY, Novo Nordisk, acquisition, merger, biotechnology, pharmaceutical, drug development, regulatory approval, SEC filing, 10-Q, financial results, R&D, cash, stock options, intellectual property, corporate governance, legal proceedings, healthcare regulation, capital raise